Brentuximab Vedotin
Last Updated: 11/08/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1890 publications
Diagnosis and management of peripheral T-cell lymphoma
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Published: October 28, 2026
Outcomes of brentuximab vedotin in cutaneous T-cell lymphoma: A Middle Eastern real-world study.
Journal: JAAD international
Published: October 11, 2026
Recurrent Hypoglycemia and Hypercalcemia As Presenting Features of CD30-Positive Peripheral T-cell Lymphoma, Not Otherwise Specified.
Journal: Cureus
Published: October 01, 2026
Hypereosinophilic syndrome and suspected myeloid neoplasia in relapsed Hodgkin lymphoma during immune checkpoint inhibitor therapy: a rare case.
Journal: Leukemia & lymphoma
Published: August 30, 2026
Successful treatment of refractory hemophagocytic lymphohistiocytosis complicating Epstein-Barr virus-positive classic Hodgkin lymphoma with rituximab.
Journal: Journal of clinical and experimental hematopathology : JCEH
Published: August 30, 2026
Incidence of clinically significant chemotherapy induced nausea and vomiting with brentuximab vedotin and AVD in comparison with ABVD using standard anti-emetic prophylaxis.
Journal: Leukemia & lymphoma
Published: August 24, 2026
Clinical study of brentuximab vedotin combined with the ifosfamide and gemcitabine regimen in the treatment of children with relapsed or refractory classic Hodgkin lymphoma
Journal: Zhonghua er ke za zhi = Chinese journal of pediatrics
Published: August 17, 2026
Primary ALK-positive anaplastic large cell lymphoma of the urinary bladder in a pediatric patient: a case report and review of literature.
Journal: Journal of hematopathology
Published: August 13, 2026
Nivolumab + Doxorubicin, Vinblastine, and Dacarbazine in HIV-Associated Advanced-Stage Classic Hodgkin Lymphoma.
Journal: JCO oncology advances
Published: August 11, 2026
Last Updated: 11/08/2026